Skip to main content

Table 5 Characteristic and therapeutic effect of patients receiving intravenous PMB among centers

From: Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

  Value for: P
Sub-centers (n = 83) Main center (n = 17)
Mechanical ventilation, n (%) 44 (53.01) 7 (41.18) 0.432
Septic shock, n (%) 40 (48.19) 9 (52.94) 0.721
Adverse events, n (%) 14 (16.87) 2 (11.76) 0.601
Non-survivors, n (%) 33 (39.75) 7 (41.18) 0.222